{"id":829988,"date":"2025-03-26T08:36:36","date_gmt":"2025-03-26T12:36:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/"},"modified":"2025-03-26T08:36:36","modified_gmt":"2025-03-26T12:36:36","slug":"cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/","title":{"rendered":"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session"},"content":{"rendered":"

<\/p>\n

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th<\/sup> Annual Scientific Session<\/b><\/p>\n

CHICAGO–(BUSINESS WIRE<\/a>)–Cardio Diagnostics Holdings, Inc.<\/a> (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced its participation in the American College of Cardiology\u2019s 74th Annual Scientific Session & Expo (ACC.25)<\/a>, taking place March 29-31, 2025, at McCormick Place in Chicago, IL. Cardio Diagnostics will be exhibiting at Booth #2033, showcasing its growing portfolio of advanced cardiovascular solutions, focusing on the Company\u2019s PrecisionCHD\u2122 test and its enhanced Actionable Clinical Intelligence (ACI\u2122) report designed to transform how coronary heart disease (CHD) is diagnosed and managed.\n<\/p>\n

\nCardio Diagnostics\u2019 mission is to redefine cardiovascular care by combining epigenetics, genetics, and artificial intelligence to enable earlier detection of heart disease and more personalized patient management. Through our commitment to data-driven innovation, Cardio Diagnostics aims to prevent heart disease, improve diagnostic accuracy, and enable clinicians with actionable insights to deliver targeted, effective care.\n<\/p>\n

Spotlight on PrecisionCHD\u2122 and Actionable Clinical Intelligence (ACI\u2122)<\/b><\/p>\n

\nPrecisionCHD\u2122, Cardio Diagnostics\u2019 flagship solution, is a clinical blood test available by prescription to aid in the diagnosis and management of coronary heart disease (CHD). Unlike traditional diagnostic tools, PrecisionCHD\u2122 is radiation-free, requires no fasting, and is performed through a simple blood draw, either via standard phlebotomy or lancet-based sampling. By evaluating a unique panel of 10 genetic and 6 epigenetic (DNA methylation) markers, PrecisionCHD\u2122 provides clinicians with deep insights into the unique underlying molecular drivers of CHD for each patient.\n<\/p>\n

\nImportantly, the test results map epigenetic biomarkers to modifiable risk factors, allowing clinicians to personalize patient management. For cardiologists, PrecisionCHD\u2122 serves as a critical tool in the fight against CHD, offering a non-invasive, radiation-free method to assess molecular drivers of CHD that traditional diagnostics may overlook. With the ability to track changes over time, PrecisionCHD\u2122 empowers cardiologists to refine treatment plans based on a patient\u2019s unique epigenetic profile, ultimately driving more effective interventions and better long-term cardiovascular outcomes.\n<\/p>\n

\nThis year at ACC.25, Cardio Diagnostics will specifically highlight the updated Actionable Clinical Intelligence (ACI\u2122) report for PrecisionCHD\u2122, now enhanced to provide clearer, easier-to-interpret and more actionable clinical insights. The updated ACI\u2122 leverages PrecisionCHD\u2122\u2019s six key methylation markers, giving prescribing clinicians sharper visibility into their patients\u2019 modifiable drivers of disease, including inflammation-related risk – a critical advancement for personalized care.\n<\/p>\n

\n\u201cPrecisionCHD\u2122 and our enhanced Actionable Clinical Intelligence\u2122 deliver a level of insight that no other solution offers cardiologists today,\u201d said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. \u201cBy integrating epigenetics, genetics, and AI, we provide a clearer, more actionable understanding of a patient\u2019s modifiable drivers of coronary heart disease. This empowers cardiologists to deliver truly personalized care and improve patient outcomes.\u201d\n<\/p>\n

Poster Presentation – Methylation Biomarkers as Predictors of Mortality in ACS Patients: A Critical Advancement for Clinical Cardiology<\/b><\/p>\n

\nAt ACC.25, Cardio Diagnostics will present compelling new data on the power of the methylation biomarkers of the PrecisionCHD\u2122 test to predict mortality in patients with Acute Coronary Syndrome (ACS), offering cardiologists a novel, actionable tool to guide patient management to help improve survival outcomes.\n<\/p>\n

\nThe poster, titled \u201cSynergistic Effects of Combining Methylation Data with Imaging Data in Predicting Mortality of Acute Coronary Syndrome (ACS) Patients,\u201d highlights findings from a recent study by Cardio Diagnostics demonstrating the superiority of PrecisionCHD methylation indices to angiographic methods for predicting mortality risk in ACS patients. In addition, the study delineates a machine learning-based method that could be integrated within existing electronic health records systems to synergistically combine angiographic and methylation information for predicting mortality risk.\n<\/p>\n

\nBy interrogating key methylation pathways linked to inflammation and coronary heart disease, PrecisionCHD\u2122 can enable clinicians to more effectively stratify mortality risk and personalize treatment plans for ACS patients, potentially improving outcomes.\n<\/p>\n

\n\u201cThese findings underscore the power of methylation-based biomarkers in cardiovascular medicine,\u201d said Rob Philibert, M.D., Ph.D., Chief Medical Officer of Cardio Diagnostics. \u201cTraditional imaging tools provide valuable anatomical insights, but they fall short in predicting long-term mortality risk and providing mechanistic insights. Our study shows that methylation biomarkers not only fill this gap but also offer a more precise, biologically driven assessment of mortality risk, allowing cardiologists to intervene earlier and more effectively.\u201d\n<\/p>\n

Visit Cardio Diagnostics at Booth #2033<\/b><\/p>\n

\nAttendees are invited to visit Booth #2033 to learn more about the Company\u2019s PrecisionCHD\u2122, Epi+Gen CHD\u2122 and Actionable Clinical Intelligence\u2122 solutions, and its broader vision for AI-driven, epigenetic-guided precision cardiovascular medicine. The Company\u2019s executive team will also be onsite to engage with cardiologists, potential partners and attendees on how these innovations are transforming cardiovascular care.\n<\/p>\n

About Cardio Diagnostics<\/b><\/p>\n

\nCardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (\u201cCore Technology\u201d) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https:\/\/cdio.ai\/<\/a><\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nCertain statements and information included in this press release constitute \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases \u201cwill\u201d, \u201cwill likely result,\u201d \u201cexpected to,\u201d \u201cwill continue,\u201d \u201canticipated,\u201d \u201cestimate,\u201d \u201cprojected,\u201d \u201cintend,\u201d \u201cgoal,\u201d or similar expressions are intended to identify \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, under the heading \u201cRisk Factors\u201d in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company\u2019s financial performance and could cause the Company\u2019s actual results for future periods to differ materially from any opinions or statements expressed within this press release.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250326097652\/en\/<\/a><\/span><\/p>\n

Investors:
\n<\/b>
Investor Relations
\n
855-226-9991
\n
investors@cdio.ai<\/a><\/p>\n

Media & Public Relations
\n<\/b>
Public Relations
\n
855-226-9991
\n
pr@cdio.ai<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Illinois<\/p>\n

INDUSTRY KEYWORDS:<\/b> Software Research Medical Devices Technology Artificial Intelligence Genetics Health Technology Clinical Trials Science Cardiology Biotechnology Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced its participation in the American College of Cardiology\u2019s 74th Annual Scientific Session & Expo (ACC.25), taking place March 29-31, 2025, at McCormick Place in Chicago, IL. Cardio Diagnostics will be exhibiting at Booth #2033, showcasing its growing portfolio of advanced cardiovascular solutions, focusing on the Company\u2019s PrecisionCHD\u2122 test and its enhanced Actionable Clinical Intelligence (ACI\u2122) report designed to transform how coronary heart disease (CHD) is diagnosed and managed. Cardio Diagnostics\u2019 mission is to redefine cardiovascular care by combining epigenetics, genetics, … <\/p>\n

Continue reading “Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829988","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced its participation in the American College of Cardiology\u2019s 74th Annual Scientific Session & Expo (ACC.25), taking place March 29-31, 2025, at McCormick Place in Chicago, IL. Cardio Diagnostics will be exhibiting at Booth #2033, showcasing its growing portfolio of advanced cardiovascular solutions, focusing on the Company\u2019s PrecisionCHD\u2122 test and its enhanced Actionable Clinical Intelligence (ACI\u2122) report designed to transform how coronary heart disease (CHD) is diagnosed and managed. Cardio Diagnostics\u2019 mission is to redefine cardiovascular care by combining epigenetics, genetics, … Continue reading "Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T12:36:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session\",\"datePublished\":\"2025-03-26T12:36:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/\"},\"wordCount\":1121,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/\",\"name\":\"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-03-26T12:36:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/","og_locale":"en_US","og_type":"article","og_title":"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session - Market Newsdesk","og_description":"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced its participation in the American College of Cardiology\u2019s 74th Annual Scientific Session & Expo (ACC.25), taking place March 29-31, 2025, at McCormick Place in Chicago, IL. Cardio Diagnostics will be exhibiting at Booth #2033, showcasing its growing portfolio of advanced cardiovascular solutions, focusing on the Company\u2019s PrecisionCHD\u2122 test and its enhanced Actionable Clinical Intelligence (ACI\u2122) report designed to transform how coronary heart disease (CHD) is diagnosed and managed. Cardio Diagnostics\u2019 mission is to redefine cardiovascular care by combining epigenetics, genetics, … Continue reading \"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-26T12:36:36+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session","datePublished":"2025-03-26T12:36:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/"},"wordCount":1121,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/","name":"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-03-26T12:36:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250326097652r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardio-diagnostics-holdings-inc-to-showcase-enhanced-precisionchd-actionable-clinical-intelligence-and-new-clinical-advancements-at-the-american-college-of-cardiologys-74\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD\u2122, Actionable Clinical Intelligence\u2122 and New Clinical Advancements at the American College of Cardiology\u2019s 74th Annual Scientific Session"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829988"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829988\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}